Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa · 2026
Read Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy by Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13670883.txt.
Description
Some proteins that control gene activity are called undruggable because medicines cannot grip them. Gabriel Serra-Mir and co-authors sidestep that problem in a 2026 cancer study by delivering the protein's blueprint instead. They package messenger RNA for a factor called LCOR, which suppresses tumor growth and helps tumor cells show themselves to the immune system.
Tiny polymer particles carried the RNA into breast cancer cells in lab and animal tests, restoring the factor's work. Treated tumors grew less. When the RNA therapy was combined with standard immunotherapy drugs in a hard-to-treat breast cancer model, most tumors were wiped out. The authors present the approach as a replacement therapy: supply the missing controller, and let the immune system finish the job.
Catalog record
| CREATOR | Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 68 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |